These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 26788788)
41. [PREVENTION OF PRETERM BIRTH IN TWINS WITH SHORT MID-TRIMESTER CERVICAL LENGTH LESS THAN 25MM -COMBINED TREATMENT WITH ARABIN'S CERCLAGE PESSARY AND INTRAVAGINAL MICRONIZED PROGESTERONE COMPARED WITH CONSERVATIVE TREATMENT]. Zimerman A; Maymon R; Viner Y; Glick N; Herman A; Neeman O Harefuah; 2018 May; 157(5):301-304. PubMed ID: 29804334 [TBL] [Abstract][Full Text] [Related]
43. Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data meta-analysis. Romero R; Conde-Agudelo A; Rehal A; Da Fonseca E; Brizot ML; Rode L; Serra V; Cetingoz E; Syngelaki A; Tabor A; Perales A; Hassan SS; Nicolaides KH Ultrasound Obstet Gynecol; 2022 Feb; 59(2):263-266. PubMed ID: 34941003 [No Abstract] [Full Text] [Related]
44. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Senat MV; Porcher R; Winer N; Vayssière C; Deruelle P; Capelle M; Bretelle F; Perrotin F; Laurent Y; Connan L; Langer B; Mantel A; Azimi S; Rozenberg P; Am J Obstet Gynecol; 2013 Mar; 208(3):194.e1-8. PubMed ID: 23433324 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial. Cabrera-García L; Cruz-Melguizo S; Ruiz-Antorán B; Torres F; Velasco A; Martínez-Payo C; Avendaño-Solá C; Trials; 2015 Sep; 16():427. PubMed ID: 26407852 [TBL] [Abstract][Full Text] [Related]
46. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. Lim AC; Bloemenkamp KW; Boer K; Duvekot JJ; Erwich JJ; Hasaart TH; Hummel P; Mol BW; Offermans JP; van Oirschot CM; Santema JG; Scheepers HC; Schöls WA; Vandenbussche FP; Wouters MG; Bruinse HW; BMC Pregnancy Childbirth; 2007 Jun; 7():7. PubMed ID: 17578562 [TBL] [Abstract][Full Text] [Related]
47. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database. Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341 [TBL] [Abstract][Full Text] [Related]
48. Progesterone for preterm birth prevention. Ransom CE; Murtha AP Obstet Gynecol Clin North Am; 2012 Mar; 39(1):1-16, vii. PubMed ID: 22370103 [TBL] [Abstract][Full Text] [Related]
49. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Hall NR Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799 [TBL] [Abstract][Full Text] [Related]
50. Short cervical length dilemma. Suhag A; Berghella V Obstet Gynecol Clin North Am; 2015 Jun; 42(2):241-54. PubMed ID: 26002164 [TBL] [Abstract][Full Text] [Related]
51. [Cervical pessary and prevention of preterm birth]. Sentilhes L; Descamps P; Legendre G Gynecol Obstet Fertil; 2014 Jan; 42(1):38-44. PubMed ID: 24309029 [TBL] [Abstract][Full Text] [Related]
52. Universal cervical length screening in singleton gestations without a previous preterm birth: ten reasons why it should be implemented. Khalifeh A; Berghella V Am J Obstet Gynecol; 2016 May; 214(5):603.e1-5. PubMed ID: 26707072 [TBL] [Abstract][Full Text] [Related]
53. Vaginal progesterone for prevention of preterm birth in asymptomatic high-risk women with a normal cervical length: a systematic review and meta-analysis protocol. Williams KP; McAuliffe L; Diacci R; Aubin AM; Issah A; Wang C; Phung J; Pennell CE Syst Rev; 2021 May; 10(1):152. PubMed ID: 34020724 [TBL] [Abstract][Full Text] [Related]
54. Vaginal progesterone does not prevent recurrent preterm birth in women with a singleton gestation, a history of spontaneous preterm birth, and a midtrimester cervical length >25 mm. Conde-Agudelo A; Romero R Am J Obstet Gynecol; 2022 Dec; 227(6):923-926. PubMed ID: 35926647 [No Abstract] [Full Text] [Related]
55. Prevention of preterm birth by progestational agents: what are the molecular mechanisms? Nold C; Maubert M; Anton L; Yellon S; Elovitz MA Am J Obstet Gynecol; 2013 Mar; 208(3):223.e1-7. PubMed ID: 23433326 [TBL] [Abstract][Full Text] [Related]
56. FIGO good practice recommendations on progestogens for prevention of preterm delivery. Shennan A; Suff N; Leigh Simpson J; Jacobsson B; Mol BW; Grobman WA; Int J Gynaecol Obstet; 2021 Oct; 155(1):16-18. PubMed ID: 34520058 [TBL] [Abstract][Full Text] [Related]
57. 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population. Orsulak MK; Block-Abraham D; Gee RE Clin Ther; 2015 Apr; 37(4):727-32. PubMed ID: 25700945 [TBL] [Abstract][Full Text] [Related]
58. Matched sample comparison of intramuscular versus vaginal micronized progesterone for prevention of preterm birth. El-Gharib MN; El-Hawary TM J Matern Fetal Neonatal Med; 2013 May; 26(7):716-9. PubMed ID: 23205864 [TBL] [Abstract][Full Text] [Related]
59. Systemic progesterone therapy--oral, vaginal, injections and even transdermal? Ruan X; Mueck AO Maturitas; 2014 Nov; 79(3):248-55. PubMed ID: 25113944 [TBL] [Abstract][Full Text] [Related]